ClinicalTrials.gg
Status unknownNCT05015309Updated Aug 20, 2021

A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor

A Phase 1 interventional study of SH3765 tablet in Advanced Malignant Tumor, sponsored by Nanjing Sanhome Pharmaceutical, Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-20.

Sponsored by Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective is to determine the safety and tolerability of SH3765 in subjects with advanced malignant tumor by determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The second objective is to evaluate the PK profile and preliminary efficacy of SH3765 in subjects with advanced malignant tumor.

Read the detailed description

This is a Phase I, open-label, multicenter, multidose, two-part study to assess the safety, tolerability, PK and preliminary efficacy of SH3765, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in subjects with advanced malignant tumor including but not limited to solid tumor and non-Hodgkin lymphoma.

02

Conditions studied

  • Advanced Malignant Tumor
03

In context

Lead sponsor

Nanjing Sanhome Pharmaceutical, Co., Ltd. is the lead sponsor of 23 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years;
  2. Patients must have a or cytologically confirmed diagnosis of solid tumors or non-Hodgkin lymphomas (NHLs), with the following criteria specific to each tumor type:

    For solid tumors: Patients must have advanced triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), adenoid cystic carcinoma (ACC), prostate cancer (PC), or head and neck squamous cell carcinoma (HNSCC). The must be relapsed or refractory after at least 1 prior line of anti-tumor therapy, and for which there are no available standard of care therapy or therapies known to provide clinical benefit; For NHLs: Patients must have mantle cell lymphoma (MCL), or non-germinal center B-cell-like (non-GCB) subtypes of diffuse large B-cell lymphoma (DLBCL) (both de novo and transformed non-GCB DLBCL are allowed). The malignancy must be relapsed or refractory after at least 2 prior lines of anti-tumor therapy, and for which there are no available standard of care therapy or therapies known to provide clinical benefit. The patients who require urgent cytoreductive therapy will be excluded, unless the patient has no remaining treatment choice with potential benefits.

  3. Patients must provide , if available, from the most recent biopsy, or are able to undergo a tumor biopsy during screening;
  4. At least one evaluable or measurable tumor lesion;
  5. (ECOG) Performance Status of 0 to 1;
  6. ≥3 months;
  7. Adequate hematological and biological function, confirmed by the following laboratory values (Have not received blood transfusion or hematopoietic stimulating factor treatment within 14 days): ≤1.0×; Total (TBIL) ≤1.5×ULN if no demonstrable liver lesion(s) (primary or ) or ≤3×ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver lesion(s); (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN if no demonstrable liver lesion(s) (primary or metastases) or ≤5×ULN in the presence of liver lesion(s); ≥50mL/min (Calculated according to Cockcroft-Gault formula); (LVEF) ≥50%; corrected using Fridericia's method (QTcF)\<470 msec; For advanced solid tumors patients: ≥1.5×109/L, ≥100×109/L, (Hb) ≥90 g/L; For advanced non-Hodgkin lymphoma patients: ANC ≥ 1.0×109/L, PLT ≥ 80×109/L, Hemoglobin (Hb) ≥80 g/L;
  8. Women of child bearing potential must agree to use a reliable form of during the study treatment period and for at least 180 days following the last dose of study drug, and 3 days before treatment the pregnancy tests are negative. Men must agree to the use of male contraception during the study treatment period and for at least 180 days after the last dose of study drug;
  9. Not using any other drugs within 30 days before the study drugs administration;
  10. Be informed of the trial before the start of the trial, and voluntarily sign the name and date on the form.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with PRMT5 inhibitors;
  2. Anticancer treatment including radiation therapy, chemotherapy, hormonal therapy, molecular targeted therapy, or immunotherapy within 3 weeks before the first dose of SH3765 (use of mitomycin or nitrosoureas within 6 weeks before the first dose; use of oral fluorouracil, such as tegafur and capecitabine, within 2 weeks before the first dose; use herbal medicine with anti-tumor indications within 2 weeks before the first dose);
  3. Evidence of central nervous system (CNS) ;
  4. Evidence of any severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, uncontrolled pleural effusion and ascites, uncontrolled diabetes, non-infectious pneumonia, or any other severe cardiovascular, respiratory, nervous and mental diseases;
  5. Have severe cardiac disease: class ≥grade II heart failure; arrhythmia requiring medical treatment; myocardial infarction or unstable angina pectoris within 6 months; currently taking known extension drugs those who cannot stop the drug for at least 5 half-lives before starting the study drug treatment;
  6. Patients who have active infection within 1 week before the first administration and need systematic anti-infection treatment;
  7. Active infection with virus (HBV), virus (HCV) or (HIV). Patients with HBsAg positive but HBV-DNA negative, or with HCV antibody positive but HCV-RNA negative, or with HIV antibody positive but HIV-RNA negative and normal will be inclusive;
  8. Patients who received systemic (prednisone >10 mg/ day or equivalent dose of the same drug) or other therapy within 14 days before the first administration; except for topical, ocular, intra-articular, intranasal, and inhaled glucocorticoids; short-term use of glucocorticoids for prophylactic treatment (e.g., prevention of contrast agent allergy);
  9. The patient is currently using (or cannot stop at least 1 week prior to the first administration of the study drug) a drug known to be a strong inhibitor or inducer of and inhibitor of P-gp;
  10. Patients who received granulocyte colony stimulating factor (G-CSF) or blood transfusion therapy within 7 days before the hematologic examination at the screening stage;
  11. hematopoietic stem cell transplantation was performed within 90 days prior to the start of the study;
  12. Previous recipients of allogeneic hematopoietic stem cell transplantation or organ transplantation;
  13. According to 5.0, adverse reactions from previous anti-tumor therapy have not yet returned to ≤ grade 1 (except for toxicities which are judged by researchers to be safe, such as hair loss);
  14. Had major organ surgery (excluding puncture ) or had significant trauma within 4 weeks before the first administration, or needed to undergo surgery during the trial period;
  15. Uncontrolled nausea and vomiting, chronic gastrointestinal disease, inability to swallow pharmaceutical preparations, extensive enterectomy and possible impairment of adequate absorption of study drugs;
  16. According to CTCAE 5.0, experiencing any CTCAE grade 3 or 4 gastrointestinal bleeding in the 3 months prior to enrollment;
  17. Allergic to the similar drug or its ;
  18. Lactating women;
  19. The investigator determined that the patient should not participate in the study.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SH3765 tablet

    Daily oral administration of SH3765 tablet

    Drug: SH3765 tablet

Interventions

  • DrugSH3765 tablet

    Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    DLT is defined as an adverse event that meets protocol defined DLT criteria occurring from the first dose to the end of cycle 1 of multiple doses, except those unequivocally due to the underlying malignancy or an extraneous cause.

    Time frame: Within the first 28 days of consecutive treatment

  2. Maximum tolerated dose (MTD)

    MTD was defined as the highest dose at which DLT occurred in less than one-third of subjects during the DLT observation period.

    Time frame: Within the first 28 days of consecutive treatment

Secondary outcomes

  1. Cmax

    Highest observed plasma concentration of SH3765

    Time frame: 4 weeks

  2. Tmax

    Time of highest observed plasma concentration of SH3765

    Time frame: 4 weeks

  3. T1/2

    Elimination half-life of SH3765

    Time frame: 4 weeks

  4. Area Under the Curve (AUC)

    Area under the plasma concentration time curve of SH3765

    Time frame: 4 weeks

  5. Mean Residence Time (MRT)

    The average residence time in body of SH3765

    Time frame: 4 weeks

  6. Overall Response Rate (ORR)

    Time frame: up to 12 months

  7. Progression-free survival (PFS)

    Time frame: up to 12 months

  8. Disease control rates (DCR)

    Time frame: up to 12 months

  9. Duration of response (DOR)

    Time frame: up to 12 months

  10. Lymph node response rate (LNR)

    Time frame: up to 12 months

07

Study locations

1 site
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2021; primary completion for Mar 2023, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2021
First posted
Aug 20, 2021
StartEst.
Sep 2021
Primary completionEst.
Mar 2023
CompletionEst.
Sep 2024
Last update
Aug 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05015309
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Sep 2021 (estimated)
Primary completion
Mar 2023 (estimated)
Completion
Sep 2024 (estimated)
Last update
Aug 20, 2021

Study contacts

Ruihua Xu, PhD
Contact
xurh@sysucc.org.cn
86-20-87343468

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion